Breakthrough drugs, robotics and life-science tools
Leaders in obesity and metabolic drugs, gene-based therapies, surgical robotics and the tools behind drug discovery.
Model portfolio for research and education, not a recommendation. Returns blend each member's price change by its target weight and exclude dividends.
| Security | Weight | Price | 1D | 1M | 1Y | QuantScore | Why it's here |
|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 25% | $1,273.46 | ▼-2.54% | ▲+10.64% | ▲+55.10% | 70/100 | GLP-1 obesity and diabetes leadership |
NVO Novo Nordisk A/S | 20% | $39.05 | ▼-0.96% | ▲+2.31% | ▼-26.64% | 54/100 | Pioneer of GLP-1 treatments |
ISRG Intuitive Surgical, Inc. | 20% | $433.18 | ▲+1.52% | ▲+10.13% | ▼-5.52% |
| 59/100 |
| Installed base of surgical robots with recurring revenue |
VRTX Vertex Pharmaceuticals Incorporated | 15% | $501.95 | ▲+0.44% | ▼-1.26% | ▲+19.77% | 64/100 | Cystic fibrosis franchise and gene-editing pipeline |
REGN Regeneron Pharmaceuticals, Inc. | 10% | $782.04 | ▼-1.10% | ▼-0.36% | ▲+35.59% | 73/100 | Antibody discovery engine |
TMO Thermo Fisher Scientific Inc. | 10% | $673.82 | ▼-0.40% | ▲+1.28% | ▲+17.82% | 47/100 | Picks-and-shovels supplier to life sciences |